Clinical characteristics of second primary cancer in colorectal cancer patients: the impact of colorectal cancer or other second cancer occurring first

Li-Chu Sun1,2†, Yi-Yun Tai3†, Su-Mien Liao2, Tang-Yu Lin4, Ying-Ling Shih1,2, Se-Fen Chang5,9, Ching-Wen Huang5,6, Hon-Man Chan5,7, Che-Jen Huang5,7 and Jaw-Yuan Wang1,5,7,8,9,10*

Abstract

Background: Due to improvements in early detection, treatment, and supportive care, the number of colorectal cancer (CRC) survivors is increasing; therefore, careful attention should always be paid to the second primary cancer (SPC) in treating these CRC patients. The present study attempts to determine the correlation and clinical aspects of CRC to other cancers in patients suffering from SPC involving CRC.

Methods: From January 2002 and June 2010, 1,679 cancer cases, CRC was accompanied by SPC in 89 patients (5.3%), including 16 (18%) synchronous and 73 (82%) metachronous SPC patients. These patients were subsequently classified into two groups: the first group had CRC diagnosed first as CRC first (CRCF); and the second group had another type of cancer diagnosed before the diagnosis of CRC as other cancer first (OCF). Of these 73 patients, 22 (30.1%) were in the group of CRCF, whereas 51 (69.9%) were in the group of OCF. Patients’ clinicopathological characteristics and clinical outcomes were analyzed and compared between the two groups.

Results: There was a significant difference in the sites of cancers between the two groups: 14 (27.5%) patients in the OCF group had gastric cancer, compared to one (4.5%) patient in the CRCF group ($P = 0.026$). Although there was no difference of hepatitis B virus (HBV) or hepatitis C virus (HCV) carriers between the OCF and CRCF groups ($P = 0.165$), there were six (27.3%) CRC patients with hepatocellular carcinoma (HCC) in the CRCF group, which was significantly higher than the two (3.9%) patients in the OCF group ($P = 0.003$). Furthermore, the cancer-specific survival rate of the CRCF patient group was significantly higher than that of the OCF patient group ($P = 0.036$).

Conclusions: In this retrospective analysis, gastric cancer patients compared to other secondary cancers were at a higher risk of developing subsequent CRC as SPC; alternatively, patients with CRC were at a higher risk of developing HCC as SPC subsequently, no matter whether patients were HBV or HCV carriers. Therefore, careful attention should always be paid to the possibility of secondary CRC to construct effective surveillance when treating cancer patients.

Keywords: Colorectal cancer, Second primary cancer, Prognosis
**Background**

Colorectal cancer (CRC) is the second leading cause of cancer-related mortality in Europe and the USA, and there are approximately 300,000 new cases and 200,000 deaths due to CRC in these areas annually [1,2]. It has been reported that the incidence of CRC in economically transitioning countries continues to rise and the incidence of CRC in economically developed countries has stabilized or is declining [3]. In Taiwan, CRC was the third leading cause of cancer death and the death rate was 20.2 per 100,000 in 2010 (http://www.mohw.gov.tw/cht/DOS/Statistic.aspx?f_list_no=312&fod_list_no=2622; accessed in August 2012). There was a 24.69% increase in the CRC-related death rate in 2010 compared with that in 2002 and a 64.23% increase compared with that in 1996 [1]. In Taiwan, cancer is reported as the first leading cause of death and the death rate was 177.40 per 100,000 in 2010, over eight times the European and USA average. There was a 16.02% increase in the cancer death rate in 2010 compared with that in 2002 and a 36.04% increase compared with that in 1996 (http://www.mohw.gov.tw/cht/DOS/Statistic.aspx?flist_no=312&fodlist_no=2622; accessed in August 2012). Cancer patients are at a higher risk of developing a second cancer after the treatment of the initial cancer [1,4,5]. Due to improvements in early detection, supportive care, and multimodality treatments, the number of CRC survivors has increased in recent decades, and continuing careful attention should always be paid to the second primary cancer (SPC) in treating these CRC patients.

In recent years, reports have documented that the present percentage of SPC in the total number of cancers ranges from 0.73% to 11.70% [6] and the trend is increasing [5,7]. Compared with the general population, patients with CRC are at a higher risk of developing a SPC [8]. Thus, it is important to be aware of the clinical characteristics of SPC in CRC patients for early diagnosis and effective treatment. Several analytical studies have found interesting associations between the first tumor site and the subsequent tumors; this could be useful for prevention [9-11]. The initial characteristics of CRC as well as possible risk factors for subsequent SPC are also crucial for clinicians [12,13]. However, no relevant information regarding the differences between the sequences of CRC or SPC occurrence is available up to the present time.

In this retrospective analysis, CRC patients with at least two primary malignancies were analyzed with regard to differences of clinicopathological features and survival (CRC first or other malignancy first). We tried to identify potential risk factors and clinical outcomes which could possibly evaluate, describe, and provide appropriate postoperative surveillance strategies for CRC patients and furthermore, identify early SPC.

**Methods**

**Patients**

This retrospective cohort study included 1,679 consecutive patients with histologically proven CRC who received surgical treatment at the Department of Surgery at Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, from January 2002 to December 2010. The inclusion criteria were that each tumor had to have a definite histological picture of primary CRC and the probability that one was a metastatic lesion from the other organ must be excluded [11]. Of 1,679 cancer cases, CRC was accompanied by SPC in 89 patients (5.3%), including 16 (18%) synchronous and 73 (82%) metachronous SPC. SPC detected within 6 months after the initial cancers were regarded as synchronous cancers, and the others were categorized as metachronous cancers [10]. Therefore, 16 synchronous cancer patients were excluded for the subsequent analysis. The patients were classified into two groups: one group had CRC diagnosed first as CRC first (CRCF); and the other group had another type of cancer diagnosed before the diagnosis of CRC as other cancer first (OCF).

Patients’ clinicopathological characteristics were analyzed. Available variables included: age of onset, gender, tumor location, histological type, TNM classification of malignant tumors (TNM) defined according to the criteria of the American Joint Commission on Cancer/Union for International Cancer Control (AJCC/UICC) [14], vascular invasion, perineural invasion, preoperative serum level of albumin, preoperative serum level of carcinoembryonic antigen (CEA), comorbidity of cardiac disease, administration of chemotherapy, and body mass index (BMI). Preoperative serum levels of albumin and CEA were checked within 1 week before operation. The normal cut-off values of serum albumin and CEA were defined as 3.5 g/dL and 5 ng/mL, respectively. We reviewed all patients’ charts to identify the presence of secondary cancers. Patient clinical outcomes and survival status were regularly followed up until their last visit or death, or if the patient was lost to follow-up. This present study is a retrospective cohort study by analysis from medical records, it dose not need patients’ ICF according to Taiwan local IRB regulation after approval of the Institutional Review Board of the Kaohsiung Medical University Hospital. (KMUH-IRB-990361).

**Statistical analysis**

All data were statistically analyzed using IBM SPSS Statistics, version 17.0 (IBM Corporation, Armonk, NY, USA). For the univariate statistical analysis, chi-square test and student t-test were used where applicable for categorical and continuous variables, respectively. Cancer-specific and overall survival rates were calculated by the Kaplan–Meier method, and the differences in survival
rates were analyzed by the log-rank test. A $P$ value of less than 0.05 was considered to be statistically significant.

**Results**

The clinical and pathological data regarding CRC patients diagnosed with SPC are summarized in Table 1. There were 73 (4.3%) patients diagnosed with metachronous SPC. Sixty-eight (93.2%) patients had double cancers and five (6.8%) patients suffered from triple cancers. Of these 73 patients, 22 (30.1%) were in the group of CRCF, whereas 51 (69.9%) were in OCF. There were also no significant differences in gender, tumor size, tumor location, histological type, AJCC/UICC cancer stage, vascular invasion, perineural invasion, BMI, and comorbidity of pulmonary disease and renal disease. Meanwhile, the percentages of patients receiving adjuvant chemotherapy were not significantly different in the two groups ($P = 0.206$; Table 2). The mean age at the time of diagnosis of the first cancer was 64.0 years in the CRCF group and 58.0 years in OCF patients. Likewise, the mean age at the time of the second cancer between the two groups was not significantly different (67.0 ± 12.0 versus 66.9 ± 13.6). Between the first and second cancer there is a time lag of approximately 2.9 years in the CRCF group and 8.7 years in the OCF group, which was significantly different ($P = 0.002$; Table 2).

Table 3 shows the sites of the SPCs. In the 15 sites of SPC, gastric cancer, breast cancer, bladder cancer, and hepatocellular carcinoma (HCC) were most frequently detected, followed by cancers in the lung. The most frequent site of cancers in the group of OCF was gastric cancer, and the most frequent site of cancers in the group of CRCF were HCC and ovarian cancer. There was a significant difference in the sites of cancers in these two groups: 14 (27.5%) patients in the OCF group had gastric cancer compared to one (4.5%) patient in the CRCF group ($P = 0.026$). The comparison stage data of 15 gastric cancer patients and eight HCC patients between CRCF and OCF was not significantly different ($P = 0.232$ versus $P = 0.587$; Tables 4 and 5). Although there was no difference of hepatitis B virus (HBV) or hepatitis C virus (HCV) carriers between the OCF and CRCF ($P = 0.165$), a measure of six (27.3%) of 22 CRC patients with HCC as SPC in the CRCF group was significantly higher than two (3.9%) of 51 patients in the OCF group ($P = 0.003$). There was a significant difference in the sites of cancers in these two groups: no patients in the OCF group had ovarian cancer compared to two (9.1%) patients in the CRCF group ($P = 0.029$).

Regarding survival analysis, the cancer-specific survival of CRCF patients was significantly higher than that of the OCF patient group ($P = 0.036$; Figure 1A), but overall survival of CRCF patients was not significantly different between the two groups ($P = 0.108$; Figure 1B).

**Discussion**

Cancer-bearing patients are assumed to have an increased incidence of developing cancer of other organs [15]. In this current investigation, we identified that 5.3% of CRC patients were diagnosed with SPC, which was
consistent with previous investigations (range between 0.73% and 11.70%) [6], and the trend has been increasing in recent reports [5,7]. The most frequent sites of cancers preceding or following CRC were as follows: gastric cancer, breast cancer, bladder cancer, and HCC. In Western studies, however, different combinations of

| Parameters                          | OCF (%) | CRCF (%) | P value |
|-------------------------------------|---------|----------|---------|
| Gender                              |         |          |         |
| Male/Female                         | 23 (45.1)/28 (54.9) | 11 (50.0)/11 (50.0) | 0.700 |
| Age (years)                         |         |          |         |
| <65/≥65                             | 21 (41.2)/30 (58.8) | 10 (45.5)/12 (54.5) | 0.734 |
| Interval diagnosis time (years)     | 8.7 ± 8.32 | 2.9 ± 1.98 | 0.002 |
| HBV and HCV carrier                 |         |          |         |
| Yes/No                              | 7 (13.7)/44 (86.3) | 6 (27.3)/16 (72.7) | 0.165 |
| BMI (kg/m²)                         |         |          |         |
| <22/≥22                             | 24 (47)/27 (53) | 10 (45.5)/12 (54.5) | 0.916 |
| Albumin (gm/dL)                     |         |          |         |
| <3.5/≥3.5                           | 24 (47)/27 (53) | 8 (36.3)/14 (63.7) | 0.390 |
| Tumor size (cm)                     |         |          |         |
| ≥5/<5                               | 23 (45.1)/28 (54.9) | 6 (27.3)/16 (72.7) | 0.136 |
| Tumor location<sup>a</sup>          |         |          | 0.158  |
| Right colon                         | 15 (29.4) | 3 (13.6) |         |
| Left colon                          | 25 (49.0) | 10 (45.5) |         |
| Rectum                              | 11 (21.6) | 9 (40.9) |         |
| TNM stage                           |         |          |         |
| III + IV/II                         | 26 (51)/25 (49) | 9 (40.9)/13 (59.1) | 0.429 |
| Vascular invasion                   |         |          |         |
| Yes/No                              | 16 (31.4)/35 (68.6) | 8 (36.4)/14 (63.6) | 0.632 |
| Perineurial invasion                |         |          |         |
| Yes/No                              | 18 (35.3)/33 (64.7) | 4 (18.2)/18 (81.8) | 0.159 |
| Histology type                      |         |          |         |
| PD/WD + MD                          | 6 (11.8)/45 (88.2) | 2 (9.1)/20 (90.9) | 0.864 |
| Depth                               |         |          |         |
| T3 + T4/T1 + T2                     | 43 (84.3)/8 (15.7) | 17 (77.3)/5 (22.7) | 0.635 |
| Lymph Node                          |         |          |         |
| N1 + N2/N0                          | 23 (43.1)/28 (54.9) | 8 (36.4)/14 (63.6) | 0.488 |
| Pre-operation CEA (ng/mL)           |         |          |         |
| ≥5/<5                               | 25 (49)/26 (51) | 14 (63.6)/8 (36.4) | 0.226 |
| Chemotherapy                        |         |          |         |
| Yes/No                              | 27 (52.9)/24 (47.1) | 15 (68.2)/7 (31.8) | 0.206 |
| Diabetes mellitus                   |         |          |         |
| Yes/No                              | 11 (21.6)/40 (78.4) | 4 (18.2)/18 (81.8) | 0.742 |
| Cardiac disease                     |         |          |         |
| Yes/No                              | 5 (9.8)/46 (90.2) | 4 (18.2)/18 (81.8) | 0.318 |

<sup>a</sup>Right colon: cecum, ascending colon, and transverse colon; left colon: descending colon and sigmoid colon. BMI, body mass index; CEA, carcinoembryonic antigen; CRCF, colorectal cancer first; HBV, hepatitis B virus; HCV, hepatitis C virus; MD, moderately differentiated; OCF, other cancer first; PD, poorly differentiated; SPC, second primary cancer; TNM, TNM tumor node metastasis; WD, well differentiated.
common sites of multiple cancers are reported, most likely due to the low incidence of gastric cancer in Western populations.

Of the 51 cases in the OCF group, the stomach was the most frequent site before developing CRC as SPC. Ueno et al. indicated that when colon cancer was combined with other cancers, stomach cancer (1.4%) was the most frequently encountered neoplasm, followed by breast cancer (0.4%); and when rectal cancer was combined with other cancers, stomach cancer (0.6%) was also the most frequently encountered neoplasm, but this was followed by lung cancer (0.5%) [4]. Consequently, they suggested close follow-up to ascertain the possibility of developing secondary CRC among gastric cancer patients postoperatively. Our results are consistent with this study, since the most frequent SPC after gastric cancer was CRC. Therefore, colonoscopic examination should be arranged for the possibility of CRC in treating gastric cancer patients if they have hematochezia or ileus, in order to detect synchronous or metachronous CRC [13]. On the other hand, the liver was the most common site in CRC patients who developed SPC in the present study; however, gastric cancer remains the most frequent SPC in CRC patients from a Japanese study [4]. Despite there being no difference of HBV or HCV carriers between the OCF and CRCF, the incidence of HCC as SPC in the CRCF group was significantly higher than that in the OCF group. Patients with CRC were at a high risk of developing HCC as SPC, no matter whether the patients were HBV or HCV carriers. Follow-up strategies such as abdominal echo or computed tomography (CT) are also needed for these CRC patients to detect primary or metastatic liver lesions.

Likewise, in this study, the incidence of lung cancer together with CRC was only 0.5%, which is close to the result of the Japanese study [4]. Another study from Taiwan observed that the most common SPC in CRC patients was the liver, followed by the stomach [16]. In our study, HCC is ranked as the third leading SPC. However, only 1.26% of patients developed SPCs in another study from northern Taiwan [16]. A significantly higher proportion of Dukes’ B patients developed SPC than that of patients of other stages [16]. In our study, nine (0.53%) of TNM stage II patients developed SPC, which was not significantly different from other stages.

Birgisson et al. reveals that inclusion of SPC affects the results of cancer-specific survival rates in patients with CRC [17]; SPC generates a significant number of events during follow-up of patients with CRC, which causes worse cancer-specific survival rates when SPC is included as an event in the calculations. Almost half as many SPC cases were observed as endpoints as death from the same cancer or non-cancer-related deaths [17]. For women diagnosed with both breast cancer and CRC, the cumulative risk of death at 5 years following the second cancer diagnosis is three times more likely to be

| Parameters                  | OCF (%) | CRCF (%) | P value |
|-----------------------------|---------|----------|---------|
| Gastric cancer              | 14 (27.5) | 1 (4.5) | 0.026   |
| Hepatocellular carcinoma (HCC) | 2 (3.9) | 6 (27.3) | 0.003   |
| Breast cancer               | 10 (19.6) | 2 (9.1) | 0.266   |
| Prostate cancer             | 2 (3.9) | 0 (0)    | 0.346   |
| Cervical cancer             | 3 (5.9) | 0 (0)    | 0.245   |
| Ovarian cancer              | 0 (0)   | 2 (9.1)  | 0.029   |
| Bladder cancer              | 4 (7.8) | 4 (18.2) | 0.194   |
| Thyroid cancer              | 2 (3.9) | 2 (9.1)  | 0.373   |
| Nasal pharyngeal cancer     | 4 (7.8) | 0 (0)    | 0.177   |
| Lymphoma                    | 2 (3.9) | 1 (4.5)  | 0.902   |
| Oral cancer                 | 3 (5.9) | 1 (4.5)  | 0.818   |
| Gallbladder cancer          | 0 (0)   | 1 (4.5)  | 0.125   |
| Thymus cancer               | 0 (0)   | 1 (4.5)  | 0.125   |
| Brain cancer                | 0 (0)   | 1 (4.5)  | 0.125   |
| HBV and HCV carrier         | 7 (13.7) | 6 (27.3) | 0.165   |

CRF, colorectal cancer first; HBV, hepatitis B virus; HCV, hepatitis C virus; OCF, other cancer first; SPC, second primary cancer.

| Parameters                  | OCF (%) | CRCF (%) | P value |
|-----------------------------|---------|----------|---------|
| TNM stage I                 | 2 (14.3) | 1 (100)  | 0.232   |
| TNM stage II                | 4 (28.6) | 0 (0)    |         |
| TNM stage III               | 3 (21.4) | 0 (0)    |         |
| TNM stage IV                | 5 (35.7) | 0 (0)    |         |

CRF, colorectal cancer first; OCF, other cancer first; TNM, TNM classification of malignant tumors.

### Table 3 Site distribution of second primary cancers (SPCs) in patients with other cancer first (OCF) and colorectal cancer first (CRCF)

| Parameters                  | OCF (%) | CRCF (%) | P value |
|-----------------------------|---------|----------|---------|
| Gastric cancer              | 14 (27.5) | 1 (4.5) | 0.026   |
| Hepatocellular carcinoma (HCC) | 2 (3.9) | 6 (27.3) | 0.003   |
| Breast cancer               | 10 (19.6) | 2 (9.1) | 0.266   |
| Prostate cancer             | 2 (3.9) | 0 (0)    | 0.346   |
| Cervical cancer             | 3 (5.9) | 0 (0)    | 0.245   |
| Ovarian cancer              | 0 (0)   | 2 (9.1)  | 0.029   |
| Bladder cancer              | 4 (7.8) | 4 (18.2) | 0.194   |
| Lung cancer                 | 2 (3.9) | 2 (9.1)  | 0.373   |
| Thyroid cancer              | 5 (9.8) | 0 (0)    | 0.128   |
| Nasal pharyngeal cancer     | 4 (7.8) | 0 (0)    | 0.177   |
| Lymphoma                    | 2 (3.9) | 1 (4.5)  | 0.902   |
| Oral cancer                 | 3 (5.9) | 1 (4.5)  | 0.818   |
| Gallbladder cancer          | 0 (0)   | 1 (4.5)  | 0.125   |
| Thymus cancer               | 0 (0)   | 1 (4.5)  | 0.125   |
| Brain cancer                | 0 (0)   | 1 (4.5)  | 0.125   |
| HBV and HCV carrier         | 7 (13.7) | 6 (27.3) | 0.165   |

CRF, colorectal cancer first; HBV, hepatitis B virus; HCV, hepatitis C virus; OCF, other cancer first; SPC, second primary cancer.

### Table 4 Comparison stage of gastric cancer between other cancer first (OCF) and colorectal cancer first (CRCF)

| Parameters | OCF (%) | CRCF (%) | P value |
|------------|---------|----------|---------|
| TNM stage I | 2 (14.3) | 1 (100)  | 0.232   |
| TNM stage II | 4 (28.6) | 0 (0)    |         |
| TNM stage III | 3 (21.4) | 0 (0)    |         |
| TNM stage IV | 5 (35.7) | 0 (0)    |         |

CRCF, colorectal cancer first; OCF, other cancer first; TNM, TNM classification of malignant tumors.

### Table 5 Comparison stage of hepatocellular carcinoma (HCC) between other cancer first (OCF) and colorectal cancer first (CRCF)

| Parameters | OCF (%) | CRCF (%) | P value |
|------------|---------|----------|---------|
| TNM stage I | 0 (0)   | 1 (100)  | 0.587   |
| TNM stage II | 1 (50)  | 0 (0)    |         |
| TNM stage III | 1 (50)  | 0 (0)    |         |
| TNM stage IV | 0 (0)   | 0 (0)    |         |

CRCF, colorectal cancer first; HCC, hepatocellular carcinoma; OCF, other cancer first; TNM, TNM classification of malignant tumors.
due to CRC than to breast cancer [18]. In our study, the cancer-specific survival rate of CRCF patients was significantly higher than that of the OCF patients. The study by Tsai et al. suggests that perineural invasion may be a significant factor for postoperative early relapse of colon cancer and significantly lower overall survival rates in CRC patients [19]. Despite the cancer-specific survival rate being higher in the CRCF group, the overall survival was not significantly different between the CRCF and OCF groups in our study, and this might result from the
cause of death being non-cancer-related death (>60% after 8 years of follow-up). The event that occurred most often in patients treated with curative intention was non-cancer-related death [18].

We are left, finally, with several caveats: 1) there are few (if any) prospective controlled trials of screening strategies among patients who are at risk for second malignancies that can guide us with objective, evidence-based information about appropriate screening and management for patients with primary malignancies; 2) there is very little validated evidence that an increased screening frequency will improve outcomes among patients who develop second malignancies; and 3) the optimal screening modalities and strategies for patients who are at risk for second malignancies remain to be defined for most tumor sites. Additional investigative efforts in the future should strive to address these limitations in our current knowledge.

Conclusion

In summary, SPC in CRC remains a difficult issue for clinicians no matter whether in CRCF or OCF. In addition to a regular follow-up program, for the variety of different sites of SPC, clinicians must pay more attention to determining the potential lesions especially for the accompanying high incidence of malignancies.

Abbreviations

AJCC: American Joint Commission on Cancer; BMI: Body mass index; CEA: Carcinoembryonic antigen; CRC: Colorectal cancer; CRCF: Colorectal cancer first; CT: Computed tomography; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; HCV: Hepatitis C virus; OCF: Other cancer first; SPC: Second primary cancer; TNM: TNM classification of malignant tumors; UKCC: Union for International Cancer Control.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

LCS and YYT analyzed the data and wrote the manuscript. SML, TYL, YLS, SFC, CWH, HMC and CJH made substantial contributions to data acquisition, statistical analyses and data interpretation, and helped in manuscript preparation. JTW participated in study design and coordination. All authors read and approved the final manuscript.

Acknowledgements

This study was supported by grants from the Kaohsiung Medical University Hospital Research Foundation (KMUH99-9M10, KMUH100-OR16), the Excellence for Cancer Research Center Grant through funding by the Department of Ministry of Health and Welfare, Taiwan; Republic of China (MCHF0103-TD-B-111-05), the National Science Council, Republic of China (NSC 99-2221-B-007-014-MY3), and Biosignature in Colorectal Cancers, Academia Sinica, Taiwan.

Author details

1Department of Nutrition Support Team, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan. 2Department of Nursing, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan. 3Faculty of Post-baccalaureate Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan. 4Division of Gastrointestinal and General Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan. 5Department of Surgery, Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan. 6Department of Surgery, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan. 7Department of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan. 8Department of Surgery, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan. 9Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan. 10Cancer Center, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan.

References

1. Parkin DM: Global cancer statistics in the year 2000. Cancer Oncol 2001, 25:33–543.
2. Demandante CG, Troyer DA, Miles TP: Multiple primary malignant neoplasms: case report and a comprehensive review of the literature. Am J Clin Oncol 2003, 26:79–83.
3. Ringland CL, Arkenua HT, O’Connell DL, Ward RL: Second primary colorectal cancers (SPCrCs): experiences from a large Australian Cancer Registry. Ann Oncol 2010, 21:21–27.
4. Ueno M, Muto T, Oya M, Ota H, Azekura K, Yamaguchi T: Multiple primary cancer: an experience at the Cancer Institute Hospital with special reference to colorectal cancer. Int J Clin Oncol 2003, 8:162–167.
5. Yun HR, Yi LJ, Cho YK, Park JH, Cho YE, Yun SH, Kim HC, Chun HK, Lee WY: Double primary malignancy in colorectal cancer patients–MSI is the useful marker for predicting double primary tumors. Int J Colorectal Dis 2009, 24:369–375.
6. Hemminki K, Aaltonen L, Li K: Subsequent primary malignancies after endometrial carcinoma and ovarian carcinoma. Cancer 2003, 97:2432–2439.
7. Genovaz P, Bucher P, Neyroud-Caspar I, Soravia C, Morel P: Proximal location of colon cancer is a risk factor for development of metachronous colorectal cancer: a population-based study. Dis Colon Rectum 2005, 48:227–232.
8. Levi F, Randimbison L, Blanc-Moya R, Maspoli-Conconi M, Rosato V, Bosetti C, La Vecchia C: High constant incidence of second primary colorectal cancer. Int J Cancer 2013, 132:1679–1682.
9. Vogel VG: Identifying and screening patients at risk of second cancers. Cancer Epidemiol Biomarkers Prev 2006, 15:2027–2032.
10. Lopez ML, Lana A, Diaz S, Fougueras MV, Sanchez L, Comendador MA, Belyakova E, Rodriguez JM, Cueto A: Multiple primary cancer: an increasing health problem. Strategies for prevention in cancer survivors. Eur J Cancer Care (Engl) 2009, 18:598–605.
11. Evans HS, Moller H, Robinson D, Lewis CM, Bell CM, Hodgson SV: The risk of subsequent primary cancers after colorectal cancer in southeast England. Gut 2002, 50:647–652.
12. Das A, Chak A, Cooper GS: Temporal trend in relative risk of second primary colorectal cancer. Am J Gastroenterol 2006, 101:1342–1347.
13. Kan JY, Hsieh HS, Pan YS, Wang WM, Chen FM, Jan CM, Huang YS, Huang TJ, Wang JY: Clinical characteristics of patients with sporadic colorectal cancer and primary cancers of other organs. Jpn J Clin Oncol 2006, 36:547–553.
14. International Union Against Cancer. TNM Classification of Malignant Tumors. New York: Wiley-Liss, Inc; 6th edition; 2002.
15. Kobayashi Y, Aitkenon L, Li K: Primary site specific characteristics in second primary malignancies after colorectal cancer. Am J Clin Oncol 2009, 32:736–743.
16. Birgisson H, Wallin U, Holmberg L, Glimelius B: Survival endpoints in colorectal cancer and the effect of second primary other cancer on survival. Int J Colorectal Dis 2011, 26:547–553.
17. Belyakova E, Rodriguez JM, Cueto A: Multiple primary cancer: an increasing health problem. Strategies for prevention in cancer survivors. Eur J Cancer Care (Engl) 2009, 18:598–605.
18. Evans HS, Moller H, Robinson D, Lewis CM, Bell CM, Hodgson SV: The risk of subsequent primary cancers after colorectal cancer in southeast England. Gut 2002, 50:647–652.
19. Das A, Chak A, Cooper GS: Temporal trend in relative risk of second primary colorectal cancer. Am J Gastroenterol 2006, 101:1342–1347.
20. Kan JY, Hsieh HS, Pan YS, Wang WM, Chen FM, Jan CM, Huang YS, Huang TJ, Wang JY: Clinical characteristics of patients with sporadic colorectal cancer and primary cancers of other organs. Jpn J Clin Oncol 2006, 36:547–553.
21. International Union Against Cancer. TNM Classification of Malignant Tumors. New York: Wiley-Liss, Inc; 6th edition; 2002.
22. Kobayashi Y, Aitkenon L, Li K: Secondary primary malignancies after colorectal cancer. Am J Clin Oncol 2009, 32:736–743.
23. Chiang JM, Yeh CY, Changshien CR, Chen JS, Tang R, Tsai WS, Fan CW: Clinical features of second other-site primary cancers among sporadic colorectal cancer patients—a hospital-based study of 3,722 cases. Hepatogastroenterology 2004, 51:1341–1344.
24. Birgisson H, Wallin U, Holmberg L, Glimelius B: Survival endpoints in colorectal cancer and the effect of second primary other cancer on survival. BMC Cancer 2011, 11:438.
25. Fisher CS, Wachtel MS, Margenthaler JA: Outcomes for patients who develop both breast and colorectal cancer. Ann Surg Oncol 2012, 19:242–248.
26. Tsai HL, Chu KS, Huang YH, Sun YC, Wu JJ, Kuo CH, Chen CW, Wang JY: Predictive factors of early relapse in UICC stage I-II colorectal cancer patients after curative resection. J Surg Oncol 2009, 100:736–743.

doi:10.1186/1477-7819-12-73

Cite this article as: Sun et al.: Clinical characteristics of second primary cancer in colorectal cancer patients: the impact of colorectal cancer or other second cancer occurring first. World Journal of Surgical Oncology 2014 12:73.